

**Optimisation of retroviral gene transfer in T lymphocytes
for the redirection of PBL-specificity**

Dissertation

zur Erlangung des akademischen Grades
doctor rerum naturalium

Fachbereich Biologie, Chemie, Pharmazie
der Freien Universität Berlin

vorgelegt von

Boris Engels

Berlin 2005

1. Gutachter: Prof. Dr. T. Blankenstein

2. Gutachter: Prof. Dr. W. Uckert

Tag der Disputation: 22.08.2005

To my parents Eimelt and Jan

Contents

SUMMARY	1
ZUSAMMENFASSUNG	2
CHAPTER 1, GENERAL INTRODUCTION	3
1.1 T lymphocytes	3
1.1.1 T lymphocytes and the immune system	3
1.1.2 The T cell receptor complex and it's signalling capacity	4
1.1.3 T cell receptor variability	6
1.1.4 Antigen recognition	8
1.1.5 T cell maturation	9
1.1.6 Self-Tolerance	10
1.2 Tumour Immunology	11
1.2.1 Tumour antigens	13
1.2.1.1 Tumour-specific antigens	13
1.2.1.2 Tumour-associated antigens	15
1.3 Cancer immunotherapy	17
1.3.1 Adoptive Immunotherapy	20
1.4 Changing a T cell's specificity	21
1.4.1 Retroviral vectors	21
1.4.2 Transfer of T cell receptors	23
1.4.3 Transfer of chimeric antigen receptors	24
1.5 Renal cell carcinoma	25
1.6 Outline of this thesis	28
CHAPTER 2, HIGH-LEVEL GENE EXPRESSION IN T CELLS	30
CHAPTER 3, ENGINEERING RCC-REACTIVE CTL	45
CHAPTER 4, DISCUSSION	58
4.1 MP71 is a retroviral vector optimised for gene transfer in T lymphocytes	58
4.1.1 The impact of promoter sequences on transgene expression	59
4.1.2 The use of additional internal <i>cis</i> -regulatory elements	62
4.1.3 TCR expression and T cell avidity	65
4.1.4 Safety of retroviral vectors in gene therapy	66
4.2 Transfer of renal cell carcinoma specificity	67
4.2.1 Redirection of PBLs with TCR-26	67
4.2.2 The antigen recognised by TIL-26 is unknown	68
4.3 Engineering of T cell specificity and adoptive immunotherapy	69
4.3.1 Possibilities and limitations of adoptive T cell therapy	69
4.3.2 The importance of CD4 and CD8 T cells in anti-tumour reactions	70
4.3.3 Risks related to the adoptive transfer of redirected T cells	71
4.3.4 Limitations and potentials of CARs	73
4.4 Future prospects	76

APPENDIX	78
ABBREVIATIONS	80
REFERENCES	83
ACKNOWLEDGEMENTS	100
PUBLICATIONS	101
EIDESSTATTLICHE ERKLÄRUNG	102